首页 | 本学科首页   官方微博 | 高级检索  
     


A 12-week double-blind multi-centre study of paroxetine and imipramine in hospitalized depressed patients
Authors:S.-L. Arminen,U. Ikonen,P. Pulkkinen,E. Leinonen,A. Mahlanen,H. Koponen,K. Kourula,J. Ryypp  ,V. Korpela,M. L. Lehtonen,H. Vartiainen,V. Lehtinen,T. Tamminen,P. M. Manniche
Affiliation:S.-L. Arminen,U. Ikonen,P. Pulkkinen,E. Leinonen,A. Mahlanen,H. Koponen,K. Kourula,J. Ryyppö,V. Korpela,M. L. Lehtonen,H. Vartiainen,V. Lehtinen,T. Tamminen,P. M. Manniche
Abstract:
Fifty-seven inpatients with major depression (DSM-III-R) entered a 12-week study comparing paroxetine and imipramine. Trends (not reaching statistical significance) in favour of paroxetine were seen on the Hamilton Depression Rating Scale (HDRS) and the Montgomery-Åsberg Depression Rating Scale (MADRS). The UKU Side Effect Rating Scale showed a significant difference in favour of paroxetine on reduced salivation. Global evaluation of side effect symptoms showed that significantly more paroxetine patients had no side effects, both in the investigators’ and the patients’ opinion. These results are in line with previous findings of paroxetine being an effective and well tolerated antidepressant.
Keywords:paroxetine  imipramine  depression  serotonin  uptake  inhibition
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号